Reported 2 months ago
Recursion Pharmaceuticals, Inc. (RXRX) saw a significant increase of 11.85% in its stock price, closing at $4.91 on Wednesday, following supportive comments from analyst Jim Cramer on Mad Money. Cramer endorsed RXRX as a strong buy, highlighting the company's partnership with Nvidia and the recent FDA decision to streamline drug approval processes using artificial intelligence, positioning Recursion as a key player in the future of pharmaceuticals.
Source: YAHOO